Re: ZEN-3694 Single Agent Trial Status
in response to
by
posted on
Jan 16, 2018 08:42PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Hartland is right. The slide deck back in October first indicated that a 10 million share private placement was imminent.